AU768537B2 - Formulation comprising testosteron undecanoate and castor oil - Google Patents

Formulation comprising testosteron undecanoate and castor oil Download PDF

Info

Publication number
AU768537B2
AU768537B2 AU41111/00A AU4111100A AU768537B2 AU 768537 B2 AU768537 B2 AU 768537B2 AU 41111/00 A AU41111/00 A AU 41111/00A AU 4111100 A AU4111100 A AU 4111100A AU 768537 B2 AU768537 B2 AU 768537B2
Authority
AU
Australia
Prior art keywords
castor oil
testosterone undecanoate
liquid carrier
weight
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU41111/00A
Other languages
English (en)
Other versions
AU4111100A (en
Inventor
Susan Chandler
Josephine Joan Christine Ferdinando
Henrik Nijs De
Elizabeth Anne Perry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of AU4111100A publication Critical patent/AU4111100A/en
Application granted granted Critical
Publication of AU768537B2 publication Critical patent/AU768537B2/en
Assigned to N.V. ORGANON reassignment N.V. ORGANON Alteration of Name(s) in Register under S187 Assignors: AKZO NOBEL N.V.
Assigned to MSD OSS B.V. reassignment MSD OSS B.V. Request to Amend Deed and Register Assignors: N.V. ORGANON
Assigned to MERCK SHARP & DOHME B.V. reassignment MERCK SHARP & DOHME B.V. Request to Amend Deed and Register Assignors: MSD OSS B.V.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU41111/00A 1999-04-01 2000-03-27 Formulation comprising testosteron undecanoate and castor oil Expired AU768537B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99302581 1999-04-01
EP99302581 1999-04-01
PCT/EP2000/002677 WO2000059512A1 (en) 1999-04-01 2000-03-27 Formulation comprising testosteron undecanoate and castor oil

Publications (2)

Publication Number Publication Date
AU4111100A AU4111100A (en) 2000-10-23
AU768537B2 true AU768537B2 (en) 2003-12-18

Family

ID=8241306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41111/00A Expired AU768537B2 (en) 1999-04-01 2000-03-27 Formulation comprising testosteron undecanoate and castor oil

Country Status (26)

Country Link
EP (1) EP1189620B1 (enExample)
JP (1) JP2002541111A (enExample)
KR (1) KR100666016B1 (enExample)
CN (1) CN1155385C (enExample)
AT (1) ATE269708T1 (enExample)
AU (1) AU768537B2 (enExample)
BR (1) BR0009465A (enExample)
CA (1) CA2366856C (enExample)
CZ (1) CZ298573B6 (enExample)
DE (1) DE60011771T2 (enExample)
DK (1) DK1189620T3 (enExample)
ES (1) ES2222199T3 (enExample)
HU (1) HU229455B1 (enExample)
ID (1) ID30481A (enExample)
IL (2) IL145524A0 (enExample)
MX (1) MXPA01009919A (enExample)
NO (1) NO329420B1 (enExample)
NZ (1) NZ514290A (enExample)
PL (1) PL195163B1 (enExample)
PT (1) PT1189620E (enExample)
RU (1) RU2246296C2 (enExample)
SK (1) SK286071B6 (enExample)
TR (1) TR200102769T2 (enExample)
TW (1) TWI280124B (enExample)
WO (1) WO2000059512A1 (enExample)
ZA (1) ZA200107781B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
JO2505B1 (en) 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
US8241664B2 (en) * 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
RU2480208C2 (ru) 2006-10-04 2013-04-27 М Унд П Патент Акциенгезелльшафт Система доставки с контролируемым высвобождением для назального применения нейротрансмиттеров
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
PH12012502016A1 (en) * 2010-04-12 2013-01-21 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9119772B2 (en) * 2011-01-26 2015-09-01 Allergan, Inc. Androgen composition for treating an opthalmic condition
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP3157505B1 (en) 2014-06-17 2019-07-24 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
JP6723166B2 (ja) * 2014-06-19 2020-07-15 ソルラル ファーマ エーピーエス 親油性の化合物の固体経口剤形
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
RU2017111503A (ru) * 2014-08-29 2018-10-05 Липосин Инк. КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
AU2019308326B2 (en) * 2018-07-20 2025-07-31 Lipocine Inc. Liver disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040823A1 (en) * 1996-04-26 1997-11-06 R.P. Scherer Limited Oral pharmaceutical compositions containing sex hormones

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040823A1 (en) * 1996-04-26 1997-11-06 R.P. Scherer Limited Oral pharmaceutical compositions containing sex hormones

Also Published As

Publication number Publication date
ID30481A (id) 2001-12-13
CZ298573B6 (cs) 2007-11-14
MXPA01009919A (es) 2002-04-24
IL145524A0 (en) 2002-06-30
HU229455B1 (en) 2013-12-30
JP2002541111A (ja) 2002-12-03
HK1043544A1 (en) 2002-09-20
EP1189620A1 (en) 2002-03-27
SK286071B6 (sk) 2008-02-05
NO329420B1 (no) 2010-10-18
CA2366856A1 (en) 2000-10-12
IL145524A (en) 2006-12-31
NO20014718D0 (no) 2001-09-28
AU4111100A (en) 2000-10-23
KR100666016B1 (ko) 2007-01-10
PL195163B1 (pl) 2007-08-31
HUP0200453A3 (en) 2003-06-30
CA2366856C (en) 2006-05-16
DK1189620T3 (da) 2004-08-16
DE60011771T2 (de) 2004-11-04
TR200102769T2 (tr) 2002-05-21
TWI280124B (en) 2007-05-01
KR20010108435A (ko) 2001-12-07
BR0009465A (pt) 2002-01-08
ATE269708T1 (de) 2004-07-15
CN1155385C (zh) 2004-06-30
CN1346274A (zh) 2002-04-24
CZ20013507A3 (cs) 2002-03-13
DE60011771D1 (de) 2004-07-29
PT1189620E (pt) 2004-10-29
NZ514290A (en) 2003-08-29
NO20014718L (no) 2001-09-28
HUP0200453A2 (hu) 2002-07-29
ZA200107781B (en) 2002-12-20
PL351259A1 (en) 2003-04-07
RU2246296C2 (ru) 2005-02-20
ES2222199T3 (es) 2005-02-01
EP1189620B1 (en) 2004-06-23
WO2000059512A1 (en) 2000-10-12
SK13722001A3 (sk) 2002-02-05

Similar Documents

Publication Publication Date Title
AU768537B2 (en) Formulation comprising testosteron undecanoate and castor oil
US20050287203A1 (en) Formulation comprising testosteron undecanoate and castor oil
EP0904064B1 (en) Oral pharmaceutical compositions containing sex hormones
US11331325B2 (en) Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
JP2002541111A5 (enExample)
HK1043544B (en) Formulation comprising testosteron undecanoate and castor oil

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired